Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01185704
Other study ID # EMR200088-501
Secondary ID 2007-007932-25IN
Status Completed
Phase Phase 3
First received August 10, 2010
Last updated January 20, 2014
Start date November 2008
Est. completion date February 2012

Study information

Verified date January 2014
Source Merck KGaA
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

This is a randomized open-label study to compare between in-vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcomes of the two regimen of Cetrotide® (Cetrorelix acetate) which are 0.25 milligram (mg) used from Day 1 or Day 7 of the menstrual cycle (Day 0 or Day 6 of stimulation) in polycystic ovarian (PCO) women in assisted reproductive technology (ART).


Description:

Polycystic ovarian syndrome population is an androgenic syndrome characterized by a wide spectrum of clinical manifestations such as obesity, hirsutism, insulin resistance, diabetes and presence of specific ultrasonic features.

Cetrotide®, cetrorelix acetate, is an antagonist of luteinizing-hormone-releasing hormone (LHRH). Cetrotide® is registered in 70 countries (including France) for the prevention of premature ovulation in subjects undergoing a controlled ovarian stimulation, followed by oocyte pick-up and ARTs. Ovitrelle®, active ingredient human chorionic-gonadotropin alfa, is administered to trigger final follicular maturation and luteinization after stimulation of follicular growth.

OBJECTIVES

Primary objective:

- To compare the hormonal level of plasmatic estradiol on the releasing day (day of r-hCG administration) induced by Cetrotide® 0.25 mg/day started on Day 1 (Group A: Day 1) or on Day 7 (Group B: Day 7) of the menstrual cycle (Day 0 (S0) or Day 6 (S6) of stimulation) in PCO subjects undergoing IVF/ICSI procedures.

Secondary objectives:

- To compare the hormonal changes during the stimulation induced by Cetrotide® in A and B Groups

- To assess by ultrasound scans (US) the follicular development induced by Cetrotide® in A and B Groups

- To assess biological and clinical outcomes induced by Cetrotide® in A and B Groups

- To monitor safety of Cetrotide in A and B Groups

The trial will be conducted on an outpatient basis. Once each subject has met all eligibility criteria, they will be randomly assigned in one of the two treatment groups.


Recruitment information / eligibility

Status Completed
Enrollment 136
Est. completion date February 2012
Est. primary completion date October 2011
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria:

- Female subjects with PCO or Polycystic ovary syndrome (PCOS) according to the revised 2003 Rotterdam Consensus

- Female subjects suitable for IVF/ICSI, undergoing first or second attempt

- 18-35 years old, Body Mass Index (BMI) less than or equal to 32, non-smoking at least from Visit 0 (V0)

- Normal FSH value (less than 10 international unit per liter [IU/L]) on Day 3 of spontaneous cycle within 12 months prior to the trial

- Anti Mullerian Hormone (AMH) value (greater than 1.5 nanogram per milliliter [ng/mL]) of a spontaneous cycle within 12 months prior to the trial or at least at V0

- No history of active genito-urinary infection

- Normal thyroid function (or adequate substitution for at least 3 months)

- Negative cervical papanicolaou test within the last 12 months prior to study entry

- No gonadotropins, for at least one month prior to the trial

- No metformin therapy for at least one month prior to Visit 1 (V1)

- Subject who is able to participate in the trial and has provided written, informed consent.

Exclusion Criteria:

- Ongoing pregnancy, any pregnancy within 3 months prior to study entry, or any contraindication to pregnancy or carrying pregnancy to term

- Drilling 3 months prior to V0

- Uterine malformation, diethylstilbestrol syndrome, synechia

- Female subjects with World Health Organization (WHO) Type I or III anovulation

- Female subjects with hyperprolactinemia

- Female subjects with more than 2 recurrent miscarriages (early or late, and for any reasons)

- Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or C virus, for subject or partner

- Abnormal gynecological bleeding of undetermined origin

- History of major thromboembolic disease

- Endometriosis (Grade III or IV)

- Presence or history of malignant tumors and related treatment

- Known case of tumors of the hypothalamus or pituitary gland

- Clinically significant systemic disease or clinically significant abnormal hematology, chemistry, or urinalysis results at screening

- Known allergic reaction or hypersensitivity to Cetrotide® or Ovitrelle®

- Any active substance abuse or history of drug, medication or alcohol abuse in the past 5 years

- Participation in another clinical trial within 3 months prior to study entry.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Cetrorelix acetate
Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period [S0]) until r-hCG day (at least 2 follicles >=17 mm)
Cetrorelix acetate
Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period [S6]) until r-hCG day (at least 2 follicles >=19 mm)
Recombinant Human Choriogonadotropin (r-hCG)
The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
Recombinant human follicle stimulating hormone (r-hFSH)
Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period [S1]) until r-hCG day

Locations

Country Name City State
France Research Site Toulouse

Sponsors (2)

Lead Sponsor Collaborator
Merck KGaA Merck Serono S.A.S, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Estradiol (E2) Levels on r-hCG Day r-hCG day (end of stimulation cycle [approximately 15 days]) No
Secondary Serum Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) Levels Day 1 No
Secondary Serum Estradiol (E2) Levels Day 1 No
Secondary Serum Progesterone (P4) Levels Day 1 No
Secondary Anti Mullerian Hormone (AMH) Levels Day 0 No
Secondary Number of Follicles Greater Than or Equal (>=) to 17 mm (For Day 1 Protocol) or 19 mm (For Day 7 Protocol) on r-hCG Day r-hCG day (end of stimulation cycle [approximately 15 days]) No
Secondary Number and Quality of Oocytes Retrieved Oocyte retrieval is a technique used in in-vitro fertilization (IVF) in order to remove oocytes from the ovary of the female participant, enabling fertilization outside the body. Oocytes were classified into 4 different categories based on their quality: mature, fractured, immature and inseminated oocytes. Oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}]) No
Secondary Total Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH) Day 1 up to r-hCG day (end of stimulation cycle [approximately 15 days]) No
Secondary Percentage of Fertilized Oocytes Retrieved Oocytes were fertilized using Intra-cytoplasmic Sperm Injection (ICSI) technique which is an IVF procedure in which a single sperm is injected directly into an egg under a microscope. Oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}]) No
Secondary Number of Embryos Embryo is defined as the product of the zygote, two or three days after fertilization of the oocytes. Day 2-3 post oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}]) No
Secondary Number of Blastocysts Blastocyst is an embryo, five or six days after fertilization, with an inner cell mass, outer layer of trophectoderm and a fluid-filled blastocoele cavity. Day 5-6 post oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}]) No
Secondary Number of Transferred Embryos Embryo transfer is the procedure in which one or more embryos are placed in the uterus. Day 2-3 post Oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}]) No
Secondary Implantation Rate Implantation rate per reporting group was measured as the number of gestational sacs observed, divided by the number of embryos transferred multiplied by 100. 5 weeks post oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}]) No
Secondary Percentage of Participants With Clinical Pregnancy Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It excludes ectopic pregnancy. 10 weeks post r-hCG day (end of stimulation cycle [approximately 15 days]) No
Secondary Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. A Serious Adverse Event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. To avoid the participant/event combination double-count AEs and SAEs are reported separately. Day 1 up to end of study (15 days post last administration of study drug) Yes
See also
  Status Clinical Trial Phase
Recruiting NCT02244567 - Effect of Metformin Therapy on Serum Under-carboxylated Osteocalcin Levels in Hyperandrogenic Lean Polycystic Ovarian Syndrome Women Phase 1
Completed NCT01653743 - Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women Phase 3
Completed NCT01672801 - Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT N/A
Completed NCT00579540 - Compare Effects of Flax Seed Oil, and Fish Oil on Blood Sugar Levels N/A
Terminated NCT05084274 - Optimising Preconceptual Health in Subfertile PCOS Patients Using a Lifestyle Modification Program N/A
Completed NCT03717935 - Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS N/A
Withdrawn NCT01716429 - Healthy Eating for Reproductive Health: Greenville N/A
Active, not recruiting NCT02896452 - Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome
Recruiting NCT05146063 - LNK in Polycystic Ovary Syndrome With Insulin Resistance
Recruiting NCT06303219 - Effects of Traditional Moderate Intensity Training and High Intensity Interval Training in Polycystic Ovarian Syndrome N/A
Completed NCT02869750 - The Relationship Between Adipokines, Obesity and Insulin Resistance in Women With Polycystic Ovarian Syndrome
Completed NCT01237106 - In Vitro Maturation (IVM) for Polycystic Ovary Syndrome (PCOS) N/A
Recruiting NCT04029805 - Evaluation of a Combination of a Plant Extract and a Probiotic on Glucidic Metabolism in Women With PCOS and High Insulin Levels Phase 1/Phase 2
Completed NCT01675843 - Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome Phase 4
Completed NCT01577017 - The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS) Phase 3
Completed NCT00478504 - Letrozole Versus Clomifene Citrate for Ovulation Induction Phase 4
Completed NCT05215223 - Effect of Whole Body Vibration on Insulin Resistance in Females With Polycystic Ovarian Syndrome N/A
Completed NCT03358199 - LOD Before IVF/ICSI in PCOS Patients With High AMH N/A
Completed NCT02436226 - Use of Low Dose of HCG During Ovulation Induction With CC in Women With CC Resistant PCOS Phase 4
Recruiting NCT02084940 - Long Acting GnRH Antagonist in PCOS Women Undergoing IVF N/A